Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387473002> ?p ?o ?g. }
- W4387473002 abstract "Patients with both BRAF V600E mutations and microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) have poor prognosis. Currently, there are no specifically targeted first-line treatment options indicated for patients with mCRC whose tumors harbor both molecular aberrations. Pembrolizumab is a checkpoint inhibitor approved for the treatment of MSI-H/dMMR mCRC, and the BRAF inhibitor encorafenib, in combination with cetuximab, is approved for previously treated BRAF V600E-mutant mCRC. Combination of pembrolizumab with encorafenib and cetuximab may synergistically enhance antitumor activity in patients with BRAF V600E-mutant, MSI-H/dMMR mCRC. SEAMARK is a randomized phase II study comparing the efficacy of the combination of pembrolizumab with encorafenib and cetuximab versus pembrolizumab alone in patients with previously untreated BRAF V600E-mutant, MSI-H/dMMR mCRC.Colorectal cancer (CRC) occurs when there is an abnormal growth of cells (known as a tumor) in the colon or rectum. Some people with CRC have changes in their tumor genes (known as gene mutations). A gene is a piece of DNA that tells the cell to make specific molecules, such as proteins. Mutations in a gene called BRAF can turn on signals that help the cancer cells grow. Gene mutations that impair DNA repair mechanisms can also make the cancer cells grow more quickly and allow the immune system to detect the cancer cells as being foreign to the body. Targeted therapy is a type of cancer treatment that turns off specific genes and proteins involved in cancer cell survival and growth. BRAF and EGFR inhibitors are targeted therapies that work well together in treating people with BRAF-mutant CRC. BRAF proteins can help cancer cells grow, and BRAF inhibitors block these proteins to prevent, slow, or stop the growth of the cancer cells. Immunotherapy is a type of cancer treatment that helps a person's immune system fight cancer. Immunotherapy is effective for treating CRC that has mutations in the DNA repair mechanisms. By combining targeted therapy and immunotherapy, patients may be able to live longer without their disease getting worse. In the SEAMARK study, we will use a treatment combination including a BRAF inhibitor (encorafenib), an EGFR inhibitor (cetuximab) and an immunotherapy (pembrolizumab) in patients with CRC who have a BRAF mutation and deficiencies in the DNA repair mechanism. Clinical Trial Registration: NCT05217446 (ClinicalTrials.gov), 2021-003715-26 (EudraCT)." @default.
- W4387473002 created "2023-10-11" @default.
- W4387473002 creator A5010668711 @default.
- W4387473002 creator A5015190461 @default.
- W4387473002 creator A5021028061 @default.
- W4387473002 creator A5024180743 @default.
- W4387473002 creator A5030657436 @default.
- W4387473002 creator A5055636076 @default.
- W4387473002 creator A5062748030 @default.
- W4387473002 creator A5069877747 @default.
- W4387473002 creator A5074891676 @default.
- W4387473002 creator A5086944361 @default.
- W4387473002 creator A5088661712 @default.
- W4387473002 date "2023-10-10" @default.
- W4387473002 modified "2023-10-16" @default.
- W4387473002 title "SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR <i>BRAF</i>V600E-mutant mCRC" @default.
- W4387473002 cites W1481372545 @default.
- W4387473002 cites W1846586690 @default.
- W4387473002 cites W2014881369 @default.
- W4387473002 cites W2023660230 @default.
- W4387473002 cites W2102557111 @default.
- W4387473002 cites W2103675014 @default.
- W4387473002 cites W2103789431 @default.
- W4387473002 cites W2110682589 @default.
- W4387473002 cites W2114903025 @default.
- W4387473002 cites W2116376943 @default.
- W4387473002 cites W2122037714 @default.
- W4387473002 cites W2127437403 @default.
- W4387473002 cites W2130921932 @default.
- W4387473002 cites W2132105937 @default.
- W4387473002 cites W2133523341 @default.
- W4387473002 cites W2159064822 @default.
- W4387473002 cites W2262414037 @default.
- W4387473002 cites W2318233342 @default.
- W4387473002 cites W2400442973 @default.
- W4387473002 cites W2624834472 @default.
- W4387473002 cites W2801790772 @default.
- W4387473002 cites W2803281998 @default.
- W4387473002 cites W2889646458 @default.
- W4387473002 cites W2977895282 @default.
- W4387473002 cites W2983284890 @default.
- W4387473002 cites W3016541505 @default.
- W4387473002 cites W3110528877 @default.
- W4387473002 cites W3148370335 @default.
- W4387473002 cites W3155701827 @default.
- W4387473002 cites W3158668760 @default.
- W4387473002 cites W3160873367 @default.
- W4387473002 cites W3164333938 @default.
- W4387473002 cites W4206709614 @default.
- W4387473002 cites W4281568334 @default.
- W4387473002 cites W4297986276 @default.
- W4387473002 cites W4299544774 @default.
- W4387473002 cites W4318904231 @default.
- W4387473002 doi "https://doi.org/10.2217/fon-2022-1249" @default.
- W4387473002 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37815847" @default.
- W4387473002 hasPublicationYear "2023" @default.
- W4387473002 type Work @default.
- W4387473002 citedByCount "0" @default.
- W4387473002 crossrefType "journal-article" @default.
- W4387473002 hasAuthorship W4387473002A5010668711 @default.
- W4387473002 hasAuthorship W4387473002A5015190461 @default.
- W4387473002 hasAuthorship W4387473002A5021028061 @default.
- W4387473002 hasAuthorship W4387473002A5024180743 @default.
- W4387473002 hasAuthorship W4387473002A5030657436 @default.
- W4387473002 hasAuthorship W4387473002A5055636076 @default.
- W4387473002 hasAuthorship W4387473002A5062748030 @default.
- W4387473002 hasAuthorship W4387473002A5069877747 @default.
- W4387473002 hasAuthorship W4387473002A5074891676 @default.
- W4387473002 hasAuthorship W4387473002A5086944361 @default.
- W4387473002 hasAuthorship W4387473002A5088661712 @default.
- W4387473002 hasBestOaLocation W43874730021 @default.
- W4387473002 hasConcept C104317684 @default.
- W4387473002 hasConcept C121608353 @default.
- W4387473002 hasConcept C126322002 @default.
- W4387473002 hasConcept C143998085 @default.
- W4387473002 hasConcept C2776470698 @default.
- W4387473002 hasConcept C2777701055 @default.
- W4387473002 hasConcept C2779998722 @default.
- W4387473002 hasConcept C2780057760 @default.
- W4387473002 hasConcept C501734568 @default.
- W4387473002 hasConcept C502942594 @default.
- W4387473002 hasConcept C526805850 @default.
- W4387473002 hasConcept C54355233 @default.
- W4387473002 hasConcept C60748783 @default.
- W4387473002 hasConcept C71924100 @default.
- W4387473002 hasConcept C86803240 @default.
- W4387473002 hasConceptScore W4387473002C104317684 @default.
- W4387473002 hasConceptScore W4387473002C121608353 @default.
- W4387473002 hasConceptScore W4387473002C126322002 @default.
- W4387473002 hasConceptScore W4387473002C143998085 @default.
- W4387473002 hasConceptScore W4387473002C2776470698 @default.
- W4387473002 hasConceptScore W4387473002C2777701055 @default.
- W4387473002 hasConceptScore W4387473002C2779998722 @default.
- W4387473002 hasConceptScore W4387473002C2780057760 @default.
- W4387473002 hasConceptScore W4387473002C501734568 @default.
- W4387473002 hasConceptScore W4387473002C502942594 @default.
- W4387473002 hasConceptScore W4387473002C526805850 @default.
- W4387473002 hasConceptScore W4387473002C54355233 @default.
- W4387473002 hasConceptScore W4387473002C60748783 @default.
- W4387473002 hasConceptScore W4387473002C71924100 @default.